Androgen deprivation therapy (ADT) is no longer the standard of care for patients with metastatic hormone-sensitive prostate cancer, outside of select populations with limited life expectancy, contraindications, or personal preferences. Alicia Morgans, MD (Dana-Farber Cancer Institute) and co-authors of a Grand Rounds Paper published in the Journal of Clinical Oncology say that the initial CHAARTED (E3805) trial results (reported in 2014) and multiple phase III studies since then clearly demonstrate superior disease control and improved quality of life for combination treatments versus ADT alone.